Emily Behling, MD
Clinical FellowDownloadHi-Res Photo
About
Titles
Clinical Fellow
Education & Training
- MD
- University of Connecticut School of Medicine
- BS
- University of Connecticut, Biology
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Emily Behling's published research.
Michael Bloch, MD, MS
Angeli Landeros-Weisenberger, MD
Adam Lombroso
Victor J. Avila-Quintero, MD
Publications
2024
Systematic Review and Meta-Analysis: Placebo Response in Randomized Controlled Trials of Tourette Disorder Medications
de Barros P, Farhat L, Behling E, Nasir M, Landeros-Weisenberger A, Bloch M. Systematic Review and Meta-Analysis: Placebo Response in Randomized Controlled Trials of Tourette Disorder Medications. Journal Of The American Academy Of Child & Adolescent Psychiatry 2024 PMID: 39505141, DOI: 10.1016/j.jaac.2024.10.011.Peer-Reviewed Original ResearchConceptsDrug-placebo differencesMagnitude of placebo responseTourette's disorderPlacebo responseStandardized mean changeRandomized controlled trialsDrug responsePlacebo-controlled randomized controlled trialsDrug placeboMeta-analysisPsychiatry conditionsClinical-researchDisorder medicationsRandom-effects meta-analysisBetween-groupStandardized mean differencePharmacological interventionsStudy-level characteristicsWithin-groupPlaceboStudy-level factorsMean changeWeb of ScienceControlled trialsMean differencePharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis
Farhat L, Behling E, Landeros-Weisenberger A, de Barros P, Polanczyk G, Cortese S, Bloch M. Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis. Journal Of Child And Adolescent Psychopharmacology 2024, 34: 373-382. PMID: 39320340, DOI: 10.1089/cap.2024.0049.Peer-Reviewed Original ResearchCitationsAltmetricConceptsADHD symptomsAttention-deficit/hyperactivity disorderTic severityTourette's disorderAttention-deficit/hyperactivityRandomized controlled trialsA2 agonistPharmacological interventionsADHD symptom severityIncreased tic severityPersistent tic disordersNetwork meta-analysisStandardized mean differencePairs of medicationsEfficacy of pharmacological interventionsWorsen ticsRandom-effects network meta-analysisSymptom severityTic disordersADHDMeta-analysisNetwork meta-analysis frameworkCertainty of evidenceDisordersNetwork meta-analyses
2022
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis
Farhat L, Behling E, Landeros-Weisenberger A, Levine J, Macul Ferreira de Barros P, Wang Z, Bloch M. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. The Lancet Child & Adolescent Health 2022, 7: 112-126. PMID: 36528030, DOI: 10.1016/s2352-4642(22)00316-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSecond-generation antipsychotic drugsMedication categoriesAntipsychotic drugsModerate certaintyIndividual medicationsTourette syndromePharmacological interventionsLow certaintyWHO International Clinical Trials Registry PlatformInternational Clinical Trials Registry PlatformSystematic reviewClinical Trials Registry PlatformChoice of medicationCochrane Central RegisterNetwork meta-analysis frameworkTrials Registry PlatformRandom-effects networkTerms of tolerabilityCertainty of evidenceClinical practice guidelinesComorbid attention deficit hyperactivity disorderStandardised mean differenceTreatment of childrenAttention deficit hyperactivity disorderWeb of ScienceMeta‐Analysis: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders
Behling E, Farhat LC, Landeros‐Weisenberger A, Bloch MH. Meta‐Analysis: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders. Movement Disorders 2022, 37: 684-693. PMID: 35191552, DOI: 10.1002/mds.28957.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsChronic tic disorderTourette syndromeVMAT2 inhibitorsTic disordersVesicular monoamine transporter type 2 inhibitorsYale Global Tic Severity ScaleMean differenceRate of discontinuationTic Severity ScaleType 2 inhibitorsShort-term treatmentTic symptomsBlinded RCTEffective therapySeverity ScaleSystematic reviewTolerabilityAvailable evidenceAdverse effectsInverse varianceEfficacyRCTsInhibitorsNonsignificant effectTrialsThe effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis
Farhat LC, Flores JM, Behling E, Avila-Quintero VJ, Lombroso A, Cortese S, Polanczyk GV, Bloch MH. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Molecular Psychiatry 2022, 27: 1562-1572. PMID: 35027679, DOI: 10.1038/s41380-021-01391-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsFixed-dose trialAttention-deficit/hyperactivity disorderDose-limiting adverse eventsChildren/adolescentsAdverse eventsFlexible-dose trialTerms of efficacyClinical practiceHigh dosesFlexible dose designIntolerable adverse eventsHyperactivity disorderIncremental benefitLikelihood of discontinuationADHD symptomsLarge systematic reviewSchool-aged children/adolescentsFlexible titrationPotential long-term effectsSymptom controlTreatment discontinuationClinical outcomesStimulant dosesDaily dosesClinical guidelines
2021
Don’t Forget, Untreated Maternal Depression Poses Health Risks to the Child, Too
Behling E, Bloch MH. Don’t Forget, Untreated Maternal Depression Poses Health Risks to the Child, Too. Biological Psychiatry 2021, 90: 212-213. PMID: 34325804, DOI: 10.1016/j.biopsych.2021.06.010.Peer-Reviewed Original ResearchAltmetricMeSH Keywords